These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 3139974)
21. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Kobiler D; Gozes Y; Rosenberg H; Marcus D; Reuveny S; Altboum Z Infect Immun; 2002 Feb; 70(2):544-60. PubMed ID: 11796581 [TBL] [Abstract][Full Text] [Related]
22. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection. Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410 [TBL] [Abstract][Full Text] [Related]
24. Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Sirisanthana T; Nelson KE; Ezzell JW; Abshire TG Am J Trop Med Hyg; 1988 Dec; 39(6):575-81. PubMed ID: 3144920 [TBL] [Abstract][Full Text] [Related]
25. A bivalent protein r-PB, comprising PA and BclA immunodominant regions for comprehensive protection against Bacillus anthracis. Majumder S; Das S; Somani V; Makam SS; Joseph KJ; Bhatnagar R Sci Rep; 2018 May; 8(1):7242. PubMed ID: 29740033 [TBL] [Abstract][Full Text] [Related]
26. A Diverse Set of Single-domain Antibodies (VHHs) against the Anthrax Toxin Lethal and Edema Factors Provides a Basis for Construction of a Bispecific Agent That Protects against Anthrax Infection. Vrentas CE; Moayeri M; Keefer AB; Greaney AJ; Tremblay J; O'Mard D; Leppla SH; Shoemaker CB J Biol Chem; 2016 Oct; 291(41):21596-21606. PubMed ID: 27539858 [TBL] [Abstract][Full Text] [Related]
27. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Hanson JF; Taft SC; Weiss AA Clin Vaccine Immunol; 2006 Feb; 13(2):208-13. PubMed ID: 16467327 [TBL] [Abstract][Full Text] [Related]
28. Adenoviral Expression of a Bispecific VHH-Based Neutralizing Agent That Targets Protective Antigen Provides Prophylactic Protection from Anthrax in Mice. Moayeri M; Tremblay JM; Debatis M; Dmitriev IP; Kashentseva EA; Yeh AJ; Cheung GY; Curiel DT; Leppla S; Shoemaker CB Clin Vaccine Immunol; 2016 Jan; 23(3):213-8. PubMed ID: 26740390 [TBL] [Abstract][Full Text] [Related]
29. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax. Gorantala J; Grover S; Goel D; Rahi A; Jayadev Magani SK; Chandra S; Bhatnagar R Vaccine; 2011 Jun; 29(27):4521-33. PubMed ID: 21504775 [TBL] [Abstract][Full Text] [Related]
30. Toxin-neutralizing antibodies elicited by naturally acquired cutaneous anthrax are elevated following severe disease and appear to target conformational epitopes. Dumas EK; Demiraslan H; Ingram RJ; Sparks RM; Muns E; Zamora A; Larabee J; Garman L; Ballard JD; Boons GJ; James JA; Kayabas U; Doganay M; Farris AD PLoS One; 2020; 15(4):e0230782. PubMed ID: 32294093 [TBL] [Abstract][Full Text] [Related]
31. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of the immune response induced by a nasal anthrax vaccine based on the protective antigen protein in anaesthetized and non-anaesthetized mice. Sloat BR; Cui Z J Pharm Pharmacol; 2006 Apr; 58(4):439-47. PubMed ID: 16597361 [TBL] [Abstract][Full Text] [Related]
34. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Sloat BR; Cui Z Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616 [TBL] [Abstract][Full Text] [Related]
35. Generation of a novel chimeric PALFn antigen of Bacillus anthracis and its immunological characterization in mouse model. Suryanarayana N; Verma M; Thavachelvam K; Saxena N; Mankere B; Tuteja U; Hmuaka V Appl Microbiol Biotechnol; 2016 Oct; 100(19):8439-51. PubMed ID: 27364624 [TBL] [Abstract][Full Text] [Related]
36. Human monoclonal anti-protective antigen antibody for the low-dose post-exposure prophylaxis and treatment of Anthrax. Tang Q; Xiong S; Liang X; Kuai X; Wang Y; Wang C; Feng Z; Zhu J BMC Infect Dis; 2018 Dec; 18(1):640. PubMed ID: 30526504 [TBL] [Abstract][Full Text] [Related]
37. Development of a novel multiepitope chimeric vaccine against anthrax. Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633 [TBL] [Abstract][Full Text] [Related]
39. [Screening of full human anthrax lethal factor neutralizing antibody in transgenic mice]. Wang X; Chi X; Liu J; Liu W; Liu S; Qiu S; Wen Z; Fan P; Liu K; Song X; Fu L; Zhang J; Yu C Sheng Wu Gong Cheng Xue Bao; 2016 Nov; 32(11):1590-1599. PubMed ID: 29034628 [TBL] [Abstract][Full Text] [Related]
40. Passive vaccination with a human monoclonal antibody: generation of antibodies and studies for efficacy in Bacillus anthracis infections. vor dem Esche U; Huber M; Zgaga-Griesz A; Grunow R; Beyer W; Hahn U; Bessler WG Immunobiology; 2011 Jul; 216(7):847-53. PubMed ID: 21397977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]